{"id":"NCT00449046","sponsor":"GlaxoSmithKline","briefTitle":"Clinical Assessment Of GW815SF Salmeterol/Fluticasone Propionate(HFA MDI) In Pediatric Patients With Bronchial Asthma -A Long Term (24-week) Study-","officialTitle":"Clinical Assessment of GW815SF Salmeterol/Fluticasone Propionate (HFA MDI) in Pediatric Patients With Bronchial Asthma -A Long Term (24-week) Study-","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-03","primaryCompletion":"2007-11","completion":"2007-11","firstPosted":"2007-03-19","resultsPosted":"2009-08-04","lastUpdate":"2015-05-06"},"enrollment":40,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Bronchial Asthma"],"interventions":[{"type":"DRUG","name":"GW815SF Salmeterol/Fluticasone propionate(HFA MDI)","otherNames":[]}],"arms":[],"summary":"This study evaluates the long-term (24-week) safety and efficacy of GW815SF Salmeterol/fluticasone propionate(HFA MDI) 50/100mcg(administered as 2 inhalations of 25/50mcg) bid in pediatric patients with bronchial asthma.","primaryOutcome":{"measure":"Most Frequent Adverse Events - On Therapy","timeFrame":"Baseline to Week 24","effectByArm":[{"arm":"Salmeterol/Fluticasone Propionate","deltaMin":8,"sd":null}],"pValues":[]},"eligibility":{"minAge":"5 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":3,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1},"commonTop":["Laryngopharyngitis","Bronchitis","Nasopharyngitis","Asthma","Pharyngitis"]}}